Huge potential for oral insulin candidate, says Oramed CEO Nadav Kidron

30 May 2018

Despite an inexorable rise in the global population of type 2 diabetics, linked to changing lifestyle choices, markets for insulin are becoming ever more competitive.

As copycats fight for a slice of the action, it’s imperative for insulin firms to innovate and differentiate their offering, and the holy grail of innovation in insulin is oral delivery.

Nadav Kidron, chief executive of Israel's Oramed Pharmaceuticals (TASE: ORMP), says of his firm's lead candidate, an oral insulin that goes by the label ORMD-0801: "We've been able to show in our last trial, in 180 patients, in a statistically-significant manner, that the product works and we can deliver insulin orally."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK